OZARELIX

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C72H96ClN17O14
Molecular Weight	1459.091
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=CC=CC=C5C=C4)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O

InChI

InChIKey=KATZUZNTRINHDT-HALMFYTRSA-N

InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C72H96ClN17O14
Molecular Weight	1459.091
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://www.businesswire.com/news/home/20100127005863/en/Spectrum-Pharmaceuticals-Terminates-Ozarelix-Development-Program-Benign | https://adisinsight.springer.com/drugs/800013299 | https://www.sppirx.com/331-spectrum-products-development-ozarelix.html

Ozarelix is a luteinizing hormone-releasing hormone (LHRH) antagonist. It is known that LHRH antagonist exerts rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones. Thus this inhibitor can be effective in a variety of hormonally dependent disease including prostate cancer, benign prostatic hyperplasia (BPH), and endometriosis. Ozarelix was developed for the treatment of all these diseases including Alzheimer's disease. However, in January 2010 Spectrum Pharmaceuticals announced that it was discontinuing development of ozarelix in BPH. Because the low-dose intermittent therapy was disappointing in the treatment of lower urinary tract symptoms in men with BPH. The development of the drug for Alzheimer's disease was also discontinued. Ozarelix completed phase II trials for the treatment of prostate cancer and is in preclinical trials for the treatment of endometriosis and ovarian cancer.

Approval Year

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

Prostate Cancer: ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56. Benign Prostatic Hypertrophy: ozarelix 15 mg. given IM 2 weeks

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:59:07 UTC 2023` Edited by `admin` on `Fri Dec 15 15:59:07 UTC 2023`
Record UNII	Q1IF8M2YL3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OZARELIX

Official Name

English

AC-D-NAL(2)-D-PCL-D-PAL-SER-N-ME-TYR-D-HOMOCIT-NLE-ARG-PRO-D-ALA-NH2

Common Name

English

N-ACETYL-3-(2-NAPHTHALENYL)-D-ALANYL-4-CHLORO-D-PHENYLALANYL-3-(3-PYRIDINYL)-D-ALANYL-L-SERYL-N-METHYL-L-TYROSYL-N6-(AMINOCARBONYL)-D-LYSYL-L-NORLEUCYL-L-ARGINYL-L-PROLYL-D-ALANINAMIDE

Common Name

English

AC-D-2-NAL-D-4-CPA-D-3-PAL-SER-N-ME-TYR-D-HCI-NLE-ARG-PRO-D-ALA-NH2

Common Name

English

D-63153

Code

English

ozarelix [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2092